LAS VEGAS, April 23 /-- IMPAC Medical Systems, Inc. (IMPAC), an Elekta company and leading provider of information technology (IT) solutions for oncology care, launched its new unified cancer registry product, METRIQ, at the 2007 IMPAC Cancer Registry Users Meeting. IMPAC users from regional, state and national cancer registries can now experience the benefits of IMPAC's next generation cancer registry integrated oncology data management system, including workflow management and data analysis features and benefits.
The release of this unified cancer registry product results from years of dedicated R&D to deliver a completely new visual environment and infrastructure. METRIQ sets a new standard for oncology information management by providing a fully-integrated solution with an emphasis on multiple-vendor technology support.
METRIQ's capabilities, demonstrated at IMPAC's Cancer Registry Users Meeting, include features that streamline the entire cancer registry process from casefinding and abstracting to reporting and data analysis.
"We are proud to announce the release of METRIQ, which we know will establish a new dimension in cancer registry workflow management," stated James Hoey, President and CEO of IMPAC. "What METRIQ users gain from this product release extends beyond the basic cancer registry needs to provide a flexible system that can be configured for the unique needs of cancer programs. We've designed the framework to support full integration with oncology data management systems so our customers can optimize the information that they track for further outcomes analysis, bridging today's current needs with our future vision of cancer registry data management."
IMPAC will exhibit METRIQ cancer registry integrated oncology data management system, at the National Cancer Registrars Association (NCRA) Annual Meeting in Las Vegas, NV, April 23 - 25, 2007 and at the North American Association of Central Cancer Registries (NAACCR) Annual Conference in Detroit, MI, June 2 - 9. You may visit IMPAC's exhibit at NCRA (booth #24) and NAACCR; and attend IMPAC's presentation of "EMR Connectivity to Registry" at NAACCR.
For more information, please contact: Lorna Murdock, Marketing Communications Manager IMPAC Medical Systems, Inc. Tel: +1 408 830 8937, e-mail: email@example.com
Product Inquiries: Donna Getreuer, RN, MSN, CTR Director Product Marketing, Decision Support IMPAC Medical Systems, Inc. Tel: +1 408-830-8000, e-mail: firstname.lastname@example.org
About IMPAC Medical Systems IMPAC Medical Systems, Inc., a company in the Elekta Group, provides healthcare IT solutions that streamline clinical and business operations across the spectrum of cancer care. IMPAC's open integration to multiple healthcare data and imaging systems offers oncology-specific patient charting and practice management, as well as best-of-breed systems for anatomic pathology, clinical laboratory, and cancer registry. With products that range from diagnosis and treatment through long-term follow-up, IMPAC provides a comprehensive oncology management solution that helps improve overall communication, process efficiency, and quality patient care. For more information about IMPAC's products or services, please call 888-GO-IMPAC or visit www.impac.com
About Elekta Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.
Clinical solutions include among others Leksell Gamma Knife(R) for non- invasive treatment of brain disorders and Elekta Synergy(R) for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software. Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders. With approx. 2,000 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com